ClinicalTrials.gg
CompletedNCT05198934CodeBreak300Updated Jul 22, 2026Results posted

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

A Phase 3 interventional study of Sotorasib and Panitumumab in Colorectal Cancer (CRC), sponsored by Amgen. Completed at 105 sites in 12 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
28th of 88
160 · median 70
Started
2022
the only one that year
Phase 3
14 of 90
2 open now
Registered
82nd of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 28th largest by enrollment of the 88 interventional ones that give a count, is the only one that started in 2022, is one of 14 in phase 3, and was the 82nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).

03

Conditions studied

  • Colorectal Cancer (CRC)

Keywords

  • Sotorasib
  • AMG 510
  • Panitumumab
  • Metastatic colorectal cancer
  • Kirsten rat sarcoma p.G12C mutation
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided /assent prior to initiation of any study specific activities/procedures.
  • Age ≥18 years.
  • documented colorectal adenocarcinoma with Kirsten rat sarcoma (KRAS) p.G12C mutation as determined by prospective central testing, using the analytically validated Qiagen Therascreen KRAS RGQ polymerase chain reaction Kit in CRC as an device demonstrating a KRAS p.G12C mutation is present. Local testing and documentation of KRAS p.G12C mutation should have been previously performed as part of standard of care.
  • Participants will have received at least 1 for metastatic disease. Participants must have received and progressed or experienced disease recurrence on or after fluoropyrimidine, irinotecan, and oxaliplatin given for metastatic disease unless the participant, in the opinion of the investigator, is not a candidate for fluoropyrimidine, irinotecan, or oxaliplatin, in which case, the participant may be eligible after investigator discussion with Amgen medical monitor provided participant has received at least one prior line of therapy for metastatic disease and provided trifluridine and tipiracil or regorafenib is deemed the appropriate next line of therapy for the participant.
  • per (RECIST) 1.1 criteria. Lesions previously radiated are not considered measurable unless they have progressed after radiation.
  • (ECOG) Performance Status of ≤2.
  • of >3 months, in the opinion of the investigator.
  • Adequate hematologic and end-organ function, defined as the following within 2 weeks prior to cycle 1 day 1:

    • (ANC) ≥1.5 x 10\^9/L (without granulocyte colony stimulating factor support within 2 weeks of laboratory test used to determine eligibility).
    • ≥9.0 g/dL (without transfusion within 2 weeks of laboratory test used to determine eligibility).
    • count ≥100 x 10\^9/L (without transfusion within 2 weeks of laboratory test used to determine eligibility).
    • (AST) and alanine aminotransferase (ALT) ≤2.5 times the (ULN).
    • Serum ≤1.0 x ULN. For participants with Gilbert's disease, total bilirubin or direct bilirubin needs to be ≤1.0 x ULN.
    • (INR) and activated partial thromboplastin time (or partial thromboplastin time) ≤1.5 x ULN. Prothrombin time (PT) ≤1.5 x ULN may be used instead of INR for sites whose labs do not report INR.
    • Estimated based on Modification of Diet in Renal Disease (MDRD) calculation ≥30 mL/min/1.73 m\^2.
  • Fridericia's Correction Formula () ≤470 msec.

Exclusion criteria

Exclusion Criteria:

  • Active . Participants who have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to study day 1 are eligible if they meet all of the following criteria: a) residual neurological symptoms grade ≤2; b) on stable doses of dexamethasone or equivalent for at least 2 weeks, if applicable; and c) follow-up magnetic resonance imaging (MRI) performed within 28 days of day 1 shows no progression or new lesions appearing.
  • History or presence of hematological unless curatively treated with no evidence of disease ≥2 years.
  • History of other malignancy within the past 3 years, with the following exceptions:

    • Malignancy treated with curative intent and with no known active disease present for ≥3 years before enrollment and felt to be at low risk for recurrence by the treating physician.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated cervical carcinoma in situ without evidence of disease.
    • Adequately treated breast ductal carcinoma in situ without evidence of disease.
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer.
    • Adequately treated urothelial papillary non-invasive carcinoma or carcinoma in situ.
  • .
  • Significant gastrointestinal (GI) disorder that results in significant malabsorption, requirement for intravenous (IV) alimentation, or inability to take oral medication.
  • History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis.
  • Significant cardiovascular disease, such as cardiac disease (Class II or greater), myocardial infarction within 6 months prior to randomization, unstable arrhythmias or unstable angina.
  • Previous treatment with a KRAS G12C inhibitor.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Arm A: Sotorasib 960 mg QD + panitumumab

    Drug: Sotorasib · Drug: Panitumumab

  • Experimental
    Arm B: Sotorasib 240 mg QD + panitumumab

    Drug: Sotorasib · Drug: Panitumumab

  • Active comparator
    Arm C : Investigator's choice

    Participants will be administered trifluridine and tipiracil, or regorafenib

    Drug: Trifluridine and Tipiracil · Drug: Regorafenib

Interventions

  • Sotorasib will be administered orally

    Also known as: AMG 510, Lumakras, Lumykras

  • Panitumumab will be administered as intravenous (IV) infusion

    Also known as: Vectibix

  • DrugTrifluridine and Tipiracil

    Trifluridine and Tipiracil will be administered orally

    Also known as: Lonsurf

  • Regorafenib will be administered orally

    Also known as: Stivarga

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR

    PFS was defined as time from randomization until disease progression or death from any cause, whichever occurred first, for all participants. Progression was assessed using RECIST v1.1 per BICR.

    Time frame: From randomization until DCO or death; median (min, max) time on trial was 6.23 (0.1, 14.0) months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as time from randomization until death from any cause.

    Time frame: Approximately 3 years

  2. Objective Response Rate (ORR) Per RECIST Version 1.1 as Assessed by BICR

    Objective response was defined as best overall response (BOR) of complete response (CR) or partial response (PR), as defined by RECIST version 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters. Responses were assessed based on BICR.

    Time frame: Approximately 3 years

  3. Duration of Response (DOR) Per RECIST Version 1.1 as Assessed by BICR

    DOR was defined as time from first evidence of PR or CR until progressive disease (PD) or death due to any cause, whichever occurs first. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: Approximately 3 years

  4. Time to Response (TTR) as Assessed by BICR

    TTR was defined as time from randomization to the first evidence of PR or CR based on BICR. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.

    Time frame: Approximately 3 years

  5. Disease Control Rate (DCR) as Assessed by BICR

    DCR was defined as the percentage of participants with the BOR of CR, PR or stable disease (SD) of at least 7 weeks based on BICR. CR was defined as disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on trial (this includes baseline sum if that is the smallest on trial).

    Time frame: Approximately 3 years

  6. PFS Per RECIST Version 1.1 as Based on Investigator Assessment

    PFS by investigator assessment was defined as the time from randomization until PD or death due to any cause, whichever occurs first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the baseline SOD of target lesions.

    Time frame: Approximately 3 years

  7. ORR Per RECIST Version 1.1 as Based on Investigator Assessment

    ORR was defined as BOR of CR or PR, as defined by RECIST version 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. Responses were assessed based on investigator assessment.

    Time frame: Approximately 3 years

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were events with onset after the administration of the first dose of any trial treatment up to EOT or 30 days of the last dose of any trial treatment, or prior to first dose of crossed over treatment, whichever occurred earlier. Clinically significant changes in vital signs, and clinical laboratory tests were included as TEAEs.

    Time frame: Approximately 3 years

  9. Change From Baseline in Fatigue Severity as Measured by Item 3 of the Brief Fatigue Inventory - Short Form (BFI-SF)

    Item 3 of the BFI-SF recorded a participants' fatigue on a scale from 0 to 10. Higher scores indicated a higher severity of fatigue. An increase in score from baseline indicated a worsening of fatigue. A decrease in score from baseline indicated an improvement in fatigue.

    Time frame: Baseline and Week 8

  10. Change From Baseline in Pain Severity as Measured by Item 3 of the Brief Pain Inventory - Short Form (BPI-SF)

    Item 3 of the BPI-SF recorded a participants' pain on a scale from 1 to 10, where pain was mild (score of 1 to 4), moderate (score of 5 to 6), or severe (score of 7 to 10). An increase in score from baseline indicated a worsening of pain. A decrease in score from baseline indicates a lessening of pain.

    Time frame: Baseline and Week 8

  11. Change From Baseline in Physical Functioning as Measured by the Physical Function Domain of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire - Core 30 Item (EORTC QLQ-C30)

    The physical function domain of the EORTC QLQ-C30 assessed a participants' quality of life regarding their physical function on a scale from 1 to 4, with higher scores indicating a worse outcome. An increase in score from baseline indicated a worsening of physical functioning. A decrease in score from baseline indicated an improvement in physical functioning.

    Time frame: Baseline and Week 8

  12. Change From Baseline in Global Health Status as Measured by Questions 29 and 30 of the EORTC QLQ-C30

    Questions 29 and 30 of the EORTC QLQ-C30 assessed a participants' global health status on a scale from 1 to 7, with higher scores indicating a better outcome. An increase in score from baseline indicated an improvement in global health status. A decrease in score from baseline indicated a worsening in global health status.

    Time frame: Baseline and Week 8

  13. Change From Baseline for All Subscales of the BFI-SF

    The BFI-SF was a questionnaire that included 3 items to assess fatigue severity and 5 items to assess interference due to fatigue, with each item reported on a numeric rating scale from 0 to 10. Higher scores indicated a higher severity of fatigue. An increase in score from baseline indicated a worsening of fatigue. A decrease in score from baseline indicated an improvement in fatigue.

    Time frame: Baseline and Week 8

  14. Change From Baseline for All Subscales of the BPI-SF

    The BPI-SF was a 9-item questionnaire which included 2 body diagrams, four items to assess pain severity, four items to assess pain interference and one question about percentage of pain relief by analgesics. The level of pain and pain interference assessed could be divided into categories based on score of mild (1 to 4), moderate (5 to 6), and severe (7 to 10). An increase in score from baseline indicated a worsening of pain. A decrease in score from baseline indicated a lessening of pain.

    Time frame: Baseline and Week 8

  15. Change From Baseline for All Subscales and Domains of EORTC QLQ-C30

    The EORTC QLQ-C30 was a self-reporting 30-item generic instrument which assessed 5 functional domains (physical, role, emotional, cognitive, social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties), and a global health status/quality of life (QOL) scale. Higher scores indicated a worse outcome. An increase in score from baseline indicated a worsening of outcome. A decrease in score from baseline indicated an improvement in outcome.

    Time frame: Baseline and Week 8

  16. Average Score of VAS Scores as Measured by EQ-5D-5L

    The EQ-5D-5L questionnaire was a 2-page, standardized instrument for use as a measure of health outcome. It was comprised of a 5-dimension health status measure and a visual analogue scale. The 5-dimension health status measure evaluates: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression based on a 5-level scale: no problems, slight problems, moderate problems, severe problems, and extreme problems. The visual analogue scale recorded the participant's self-rated health on a vertical, visual analogue scale where the endpoints were labelled 'Best imaginable health state' and 'Worst imaginable health state'.

    Time frame: Baseline and Week 8

  17. Average Score on Single Question on Symptom Bother GP5 From Functional Assessment of Cancer Therapy - General (FACT-G)

    The GP5 from the FACT-G was a single item included in the Physical Well-Being subscale of the FACT-G. Responses to the item: "I am bothered by side effects of treatment" are rated on a 5-point Likert scale from "not at all" to "very much".

    Time frame: Approximately 2 years

  18. Average Score of Patient Global Impression of Change (PGIC)

    The PGIC scale consisted of one item which measures the participants' perception of change in their condition relative to the beginning of the trial. Responses are rated on a 7-item response scale ranging from very much improved to very much worse.

    Time frame: Approximately 2 years

  19. Maximum Plasma Concentration (Cmax) of Sotorasib

    Time frame: Approximately 2 years

  20. Cmax of Panitumumab

    Time frame: Approximately 2 years

  21. Area Under the Plasma Concentration-time Curve (AUC) of Sotorasib

    Time frame: Approximately 2 years

  22. AUC of Panitumumab

    Time frame: Approximately 2 years

07

Results

Posted Jul 22, 2026

Participant flow

Participants were enrolled at 67 trial centers across Asia, Europe, North America, and Australia starting on 19 April 2022. The primary analysis results presented here, for primary analysis presented here are based on data cut-off (DCO) 19 June 2023. The trial is still ongoing.

Participant flow — Overall Study
MilestoneTrifluridine and Tipiracil or RegorafenibSotorasib 240 mg + PanitumumabSotorasib 960 mg + Panitumumab
Started545353
Completed000
Not completed545353
Withdrew: Participants continuing trial293233
Withdrew: Withdrawal of consent from trial522
Withdrew: Death191818
Withdrew: Lost to follow-up110

Outcome measures

SecondaryOverall Survival (OS)

OS was defined as time from randomization until death from any cause.

Time frame:
Approximately 3 years

Results for this outcome have not been posted.

SecondaryObjective Response Rate (ORR) Per RECIST Version 1.1 as Assessed by BICR

Objective response was defined as best overall response (BOR) of complete response (CR) or partial response (PR), as defined by RECIST version 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters. Responses were assessed based on BICR.

Time frame:
Approximately 3 years

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) Per RECIST Version 1.1 as Assessed by BICR

DOR was defined as time from first evidence of PR or CR until progressive disease (PD) or death due to any cause, whichever occurs first. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
Approximately 3 years

Results for this outcome have not been posted.

SecondaryTime to Response (TTR) as Assessed by BICR

TTR was defined as time from randomization to the first evidence of PR or CR based on BICR. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.

Time frame:
Approximately 3 years

Results for this outcome have not been posted.

SecondaryDisease Control Rate (DCR) as Assessed by BICR

DCR was defined as the percentage of participants with the BOR of CR, PR or stable disease (SD) of at least 7 weeks based on BICR. CR was defined as disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on trial (this includes baseline sum if that is the smallest on trial).

Time frame:
Approximately 3 years

Results for this outcome have not been posted.

SecondaryPFS Per RECIST Version 1.1 as Based on Investigator Assessment

PFS by investigator assessment was defined as the time from randomization until PD or death due to any cause, whichever occurs first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the baseline SOD of target lesions.

Time frame:
Approximately 3 years

Results for this outcome have not been posted.

SecondaryORR Per RECIST Version 1.1 as Based on Investigator Assessment

ORR was defined as BOR of CR or PR, as defined by RECIST version 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. Responses were assessed based on investigator assessment.

Time frame:
Approximately 3 years

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were events with onset after the administration of the first dose of any trial treatment up to EOT or 30 days of the last dose of any trial treatment, or prior to first dose of crossed over treatment, whichever occurred earlier. Clinically significant changes in vital signs, and clinical laboratory tests were included as TEAEs.

Time frame:
Approximately 3 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Fatigue Severity as Measured by Item 3 of the Brief Fatigue Inventory - Short Form (BFI-SF)

Item 3 of the BFI-SF recorded a participants' fatigue on a scale from 0 to 10. Higher scores indicated a higher severity of fatigue. An increase in score from baseline indicated a worsening of fatigue. A decrease in score from baseline indicated an improvement in fatigue.

Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryChange From Baseline in Pain Severity as Measured by Item 3 of the Brief Pain Inventory - Short Form (BPI-SF)

Item 3 of the BPI-SF recorded a participants' pain on a scale from 1 to 10, where pain was mild (score of 1 to 4), moderate (score of 5 to 6), or severe (score of 7 to 10). An increase in score from baseline indicated a worsening of pain. A decrease in score from baseline indicates a lessening of pain.

Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryChange From Baseline in Physical Functioning as Measured by the Physical Function Domain of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire - Core 30 Item (EORTC QLQ-C30)

The physical function domain of the EORTC QLQ-C30 assessed a participants' quality of life regarding their physical function on a scale from 1 to 4, with higher scores indicating a worse outcome. An increase in score from baseline indicated a worsening of physical functioning. A decrease in score from baseline indicated an improvement in physical functioning.

Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryChange From Baseline in Global Health Status as Measured by Questions 29 and 30 of the EORTC QLQ-C30

Questions 29 and 30 of the EORTC QLQ-C30 assessed a participants' global health status on a scale from 1 to 7, with higher scores indicating a better outcome. An increase in score from baseline indicated an improvement in global health status. A decrease in score from baseline indicated a worsening in global health status.

Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryChange From Baseline for All Subscales of the BFI-SF

The BFI-SF was a questionnaire that included 3 items to assess fatigue severity and 5 items to assess interference due to fatigue, with each item reported on a numeric rating scale from 0 to 10. Higher scores indicated a higher severity of fatigue. An increase in score from baseline indicated a worsening of fatigue. A decrease in score from baseline indicated an improvement in fatigue.

Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryChange From Baseline for All Subscales of the BPI-SF

The BPI-SF was a 9-item questionnaire which included 2 body diagrams, four items to assess pain severity, four items to assess pain interference and one question about percentage of pain relief by analgesics. The level of pain and pain interference assessed could be divided into categories based on score of mild (1 to 4), moderate (5 to 6), and severe (7 to 10). An increase in score from baseline indicated a worsening of pain. A decrease in score from baseline indicated a lessening of pain.

Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryChange From Baseline for All Subscales and Domains of EORTC QLQ-C30

The EORTC QLQ-C30 was a self-reporting 30-item generic instrument which assessed 5 functional domains (physical, role, emotional, cognitive, social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties), and a global health status/quality of life (QOL) scale. Higher scores indicated a worse outcome. An increase in score from baseline indicated a worsening of outcome. A decrease in score from baseline indicated an improvement in outcome.

Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryAverage Score of VAS Scores as Measured by EQ-5D-5L

The EQ-5D-5L questionnaire was a 2-page, standardized instrument for use as a measure of health outcome. It was comprised of a 5-dimension health status measure and a visual analogue scale. The 5-dimension health status measure evaluates: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression based on a 5-level scale: no problems, slight problems, moderate problems, severe problems, and extreme problems. The visual analogue scale recorded the participant's self-rated health on a vertical, visual analogue scale where the endpoints were labelled 'Best imaginable health state' and 'Worst imaginable health state'.

Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryAverage Score on Single Question on Symptom Bother GP5 From Functional Assessment of Cancer Therapy - General (FACT-G)

The GP5 from the FACT-G was a single item included in the Physical Well-Being subscale of the FACT-G. Responses to the item: "I am bothered by side effects of treatment" are rated on a 5-point Likert scale from "not at all" to "very much".

Time frame:
Approximately 2 years

Results for this outcome have not been posted.

SecondaryAverage Score of Patient Global Impression of Change (PGIC)

The PGIC scale consisted of one item which measures the participants' perception of change in their condition relative to the beginning of the trial. Responses are rated on a 7-item response scale ranging from very much improved to very much worse.

Time frame:
Approximately 2 years

Results for this outcome have not been posted.

SecondaryMaximum Plasma Concentration (Cmax) of Sotorasib
Time frame:
Approximately 2 years

Results for this outcome have not been posted.

SecondaryCmax of Panitumumab
Time frame:
Approximately 2 years

Results for this outcome have not been posted.

SecondaryArea Under the Plasma Concentration-time Curve (AUC) of Sotorasib
Time frame:
Approximately 2 years

Results for this outcome have not been posted.

SecondaryAUC of Panitumumab
Time frame:
Approximately 2 years

Results for this outcome have not been posted.

PrimaryProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR

PFS was defined as time from randomization until disease progression or death from any cause, whichever occurred first, for all participants. Progression was assessed using RECIST v1.1 per BICR.

Time frame:
From randomization until DCO or death; median (min, max) time on trial was 6.23 (0.1, 14.0) months
Reported as:
Median · months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR
monthsTrifluridine and Tipiracil or RegorafenibSotorasib 240 mg + PanitumumabSotorasib 960 mg + Panitumumab
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR2.04 (1.91 to 3.91)3.91 (3.61 to 5.75)5.62 (4.21 to 6.31)

Adverse events

Collected over All-cause mortality: from randomization to min(max (death, EOS), DCO); median (min, max) time was 6.23 (0.1, 14.0) months. Adverse events includes events onset after first dose until min(last dose + 30 days, EOS, DCO); median (min, max) time was 4.70 (1.0, 13.4) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trifluridine and Tipiracil or Regorafenib20/54 (37%)15/51 (29.4%)48/51 (94.1%)
Sotorasib 240 mg + Panitumumab18/53 (34%)17/53 (32.1%)52/53 (98.1%)
Sotorasib 960 mg + Panitumumab18/53 (34%)14/53 (26.4%)52/53 (98.1%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventTrifluridine and Tipiracil or RegorafenibSotorasib 240 mg + PanitumumabSotorasib 960 mg + Panitumumab
Intestinal obstructionGastrointestinal disorders0/513/532/53
Small intestinal obstructionGastrointestinal disorders0/513/530/53
SepsisInfections and infestations0/510/533/53
DyspnoeaRespiratory, thoracic and mediastinal disorders2/510/530/53
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/511/530/53
VomitingGastrointestinal disorders0/512/530/53
PyrexiaGeneral disorders0/512/530/53
Urinary tract infectionInfections and infestations0/512/530/53
Cardiac failure acuteCardiac disorders1/510/530/53
Abdominal pain upperGastrointestinal disorders1/510/530/53
Most frequent other events
Showing 10 of 52
Most frequent other events
EventTrifluridine and Tipiracil or RegorafenibSotorasib 240 mg + PanitumumabSotorasib 960 mg + Panitumumab
Dermatitis acneiformSkin and subcutaneous tissue disorders1/5122/5313/53
NauseaGastrointestinal disorders18/5116/538/53
HypomagnesaemiaMetabolism and nutrition disorders1/5118/5318/53
NeutropeniaBlood and lymphatic system disorders17/510/530/53
RashSkin and subcutaneous tissue disorders1/5112/5316/53
DiarrhoeaGastrointestinal disorders12/5114/5314/53
Dry skinSkin and subcutaneous tissue disorders1/5114/5313/53
AnaemiaBlood and lymphatic system disorders11/518/537/53
VomitingGastrointestinal disorders6/5111/536/53
AstheniaGeneral disorders10/519/538/53

Baseline characteristics

Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)Trifluridine and Tipiracil or RegorafenibSotorasib 240 mg + PanitumumabSotorasib 960 mg + PanitumumabTotal
Mean61.5 ± 11.758.2 ± 11.960.9 ± 11.660.2 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Trifluridine and Tipiracil or RegorafenibSotorasib 240 mg + PanitumumabSotorasib 960 mg + PanitumumabTotal
Female30272481
Male24262979
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trifluridine and Tipiracil or RegorafenibSotorasib 240 mg + PanitumumabSotorasib 960 mg + PanitumumabTotal
Hispanic or Latino80412
Not Hispanic or Latino455347145
Unknown or Not Reported1023
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Trifluridine and Tipiracil or RegorafenibSotorasib 240 mg + PanitumumabSotorasib 960 mg + PanitumumabTotal
Asian1222640
Black or African American0101
White373042109
Other/Unknown50510
08

Study locations

105 sites
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California Irvine
    Orange, California 92868, United States
  • Johns Hopkins University School of Medicine
    Washington D.C., District of Columbia 20016, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • Lakes Research LLC
    Miami Lakes, Florida 33014, United States
  • Northwest Georgia Oncology Centers PC
    Marietta, Georgia 30060, United States
  • University of Michigan
    Ann Arbor, Michigan 48106-0995, United States
  • Revive Research Institute
    Farmington Hills, Michigan 48334, United States
  • Sparrow Clinical Research Institute
    Lansing, Michigan 48912, United States
  • Revive Research Institute
    Sterling Heights, Michigan 48314, United States
  • Upstate University Hospital
    Syracuse, New York 13210, United States
  • White Plains Hospital Center for Cancer Care
    White Plains, New York 10601, United States
  • Moses H Cone Memorial Hospital
    Greensboro, North Carolina 27403, United States
  • The Mark H Zangmeister Center
    Columbus, Ohio 43210, United States
  • Lancaster General Hospital Ann B Barshinger Cancer Institute
    Lancaster, Pennsylvania 17601, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Kelsey Research Foundation
    Houston, Texas 77025, United States
  • Best Cancer Care & Hematology
    Houston, Texas 77089, United States
  • Lumi Research
    Kingwood, Texas 77339, United States
  • Chris OBrien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • GenesisCare -North Shore (Oncology)
    St Leonards, New South Wales 2065, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Centre Hospitalier Universitaire de Lyon - Hopital Edouard Herriot
    Lyon Cédex 3, 69437, France
  • Institut regional du Cancer Montpellier
    Montpellier, 34298, France
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
  • Hôpital Haut -lévêque
    Pessac, 33604, France
  • Charite Universitaetsmedizin Berlin, Charité Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden
    Dresden, 01307, Germany
  • Universitaetsmedizin Goettingen - Georg-August-Universitaet
    Göttingen, 37075, Germany
  • Klinikum der Universitaet Muenchen Campus Grosshadern
    München, 81377, Germany
  • Universitaetsklinikum der Eberhard Karls Universitaet Tuebingen
    Tübingen, 72076, Germany
  • General Hospital of Athens Laiko
    Athens, 11527, Greece
  • Evgenidio Hospital I Agia Trias
    Athens, 11528, Greece
  • Hygeia Hospital
    Athens, 15123, Greece
  • University Hospital of Heraklion
    Heraklion - Crete, 71500, Greece
  • University Hospital of Patras
    Pátrai, 26504, Greece
  • Theagenion Anticancer Hospital
    Thessaloniki, 54007, Greece
  • Agios Loukas Clinic
    Thessaloniki, 55236, Greece
  • Istituto Ospedaliero Fondazione Poliambulanza
    Brescia, 25124, Italy
  • Azienda Ospedaliera Rilievo Nazionale e Alta Specializzazione Garibaldi Nesima
    Catania, 95122, Italy
  • Azienda Ospedaliera Santa Croce e Carle
    Confreria (CN), 12100, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Florence, 50134, Italy
  • Ospedale Policlinico San Martino IRCCS
    Genova, 16132, Italy
  • Azienda Sanitaria Locale 5 Spezzino Ospedale S Andrea
    La Spezia, 19100, Italy
  • Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II
    Lecce, 73100, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
    Milan, 20162, Italy
  • Azienda Ospedaliero Universitaria di Cagliari Policlinico Duilio Casula
    Monserrato CA, 09042, Italy
  • Azienda Ospedaliero Universitaria Luigi Vanvitelli
    Naples, 80131, Italy
  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale
    Naples, 80131, Italy
  • Azienda Ospedaliero Universitaria Maggiore della Carita
    Novara, 28100, Italy
  • Istituto Oncologico Veneto IRCCS
    Padova, 35128, Italy
  • Azienda Ospedaliera Universitaria Pisana Ospedale Santa Chiara
    Pisa, 56126, Italy
  • Azienda Ospedaliera San Carlo
    Potenza, 85100, Italy
  • Azienda Unita Sanitaria Locale di Reggio Emilia Arcispedale Santa Maria Nuova
    Reggio Emilia, 42100, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Azienda Ospedaliera San Giovanni Addolorata
    Roma, 00184, Italy
  • Fondazione Policlinico Tor Vergata
    Roma (RM), 00133, Italy
  • Azienda Ospedaliera Cardinale Giovanni Panico
    Tricase, 73039, Italy
  • Azienda Unita Locale Socio Sanitaria Berica 8
    Vicenza, 36100, Italy
  • Aichi Medical University Hospital
    Nagakute-shi, Aichi-ken 480-1195, Japan
  • Chiba Cancer Center
    Chiba, Chiba 260-8717, Japan
  • National Cancer Center Hospital East
    Kashiwa-shi, Chiba 277-8577, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama, Ehime 791-0280, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, Fukuoka 811-1395, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Hyogo Cancer Center
    Akashi-shi, Hyōgo 673-8558, Japan
  • St Marianna University Hospital
    Kawasaki-shi, Kanagawa 216-8511, Japan
  • Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
    Yokohama, Kanagawa 241-8515, Japan
  • National Hospital Organization Osaka National Hospital
    Osaka, Osaka 540-0006, Japan
  • Osaka University Hospital
    Suita-shi, Osaka 565-0871, Japan
  • Saitama Cancer Center
    Kitaadachi-gun, Saitama 362-0806, Japan
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka 411-8777, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research
    Koto-ku, Tokyo 135-8550, Japan
  • Health Pharma Professional Research SA de CV
    Mexico City, Mexico City 03100, Mexico
  • Superare Centro de Infusion SA de CV
    Mexico City, Mexico City 06760, Mexico
  • Trials In Medicine SC
    Mexico City, 06700, Mexico
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital Universitario Reina Sofia
    Córdoba, Andalusia 14004, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, Andalusia 18014, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Universitari Vall d Hebron
    Barcelona, Catalonia 08035, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Catalonia 08041, Spain
  • Complexo Hospitalario Universitario de Ourense
    Ourense, Galicia 32005, Spain
  • Hospital Universitario de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital General Universitario de Elche
    Elche, Valencia 03203, Spain
  • Hospital General Universitario de Valencia
    Valencia, Valencia 46014, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 80756, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation
    Taoyuan, 33305, Taiwan
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom

Showing the first 100 of 105 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Saportas Y, Tran Q, Cremolini C, Pietrantonio F. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22. PubMed 37870968 ↗
  • Pietrantonio F, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Tran Q, Cremolini C, Fakih M. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. J Clin Oncol. 2025 Jul;43(19):2147-2154. doi: 10.1200/JCO-24-02026. Epub 2025 Apr 11. PubMed 40215429 ↗
  • Modest DP, Fakih M, Salvatore L, Esaki T, Lopez-Bravo DP, Taieb J, Karamouzis M, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Tran Q, Chan E, Chao J, Majer IM, Pietrantonio F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. Lancet Oncol. 2025 Sep;26(9):1240-1251. doi: 10.1016/S1470-2045(25)00352-3. Epub 2025 Aug 11. PubMed 40812325 ↗
  • Salvatore L, Fakih M, Kuboki Y, Hong DS, Modest DP, Taieb J, Price TJ, Cremolini C, Majer IM, Rehn M, Chan E, Chen Z, Tran Q, Pietrantonio F. Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2026 Apr 23:S1533-0028(26)00026-5. doi: 10.1016/j.clcc.2026.04.003. Online ahead of print. PubMed 42173791 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jul 2025, 38 months.

Results were first posted in Jul 2026, 1 year after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 38 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2022
First posted
Jan 20, 2022
StartActual
Apr 19, 2022
Primary completionActual
Jul 16, 2025
CompletionActual
Apr 14, 2026
Results first posted
Jul 22, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05198934
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Apr 19, 2022
Primary completion
Jul 16, 2025
Completion
Apr 14, 2026
Results posted
Jul 22, 2026
Last update
Jul 22, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sotorasib · Panitumumab

Start the discussion